CBD Supplement Market Enforcement Based On FDA Concerns, Not Discretion
Although agency is prioritizing enforcement on hemp and CBD supplement and food products marketed with violative claims and allowing sales of products compliant with its regulations, the approach is not enforcement discretion, officials say. It's aware some companies are marketing hemp and CBD products "in ways that violate the law," and its "biggest concern" is products "that put the health and safety of consumers at greatest risk."
You may also be interested in...
"Technical" label violations, "full-spectrum" claims could spur class actions in CBD supplement space, says attorney Justin Prochnow. At Natural Products Expo East, he says numerous entrants have no experience and labels are likely targets as no standards are recognized for product and ingredient descriptions.
FDA policy change making hemp and CBD eligible for use a dietary ingredients should include requiring regulatory compliance by companies already marketing products with the ingredients, representatives of firms and industry trade groups said at public hearing. Requirements include submitting to FDA pre-market notifications of proof of a reasonable expectation safety for an ingredient's intended use. "Ensure the rule of law is upheld by barring any company illegally marketing CBD or hemp-derived dietary ingredients from submitting an NDI for the period of time that their products have been illegally marketed," says NOW Health exec Aaron Secrist.
As FDA moves slow on allowing CBD as a dietary ingredient, a marijuana reform law is a near-term possibility and would cause a “nuclear shift” about cannabis regulation and sway agency's decision, says cannabidiol firm CV Sciences executive.